Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates
08. November 2024 09:00 ET
|
Sana Biotechnology, Inc
Continue to advance hypoimmune technology in three trials across five indications in type 1 diabetes, B-cell mediated autoimmune diseases, and oncology Enrolling patients...
Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025
04. November 2024 16:30 ET
|
Sana Biotechnology, Inc
Prioritize clinical and preclinical development on type 1 diabetes (UP421 and SC451), B-cell mediated autoimmune diseases (SC291), refractory B-cell malignancies (SC262), and the fusogen platform for...
Sana Biotechnology to Present at the Goldman Sachs Cell Therapy Day Conference
30. September 2024 16:05 ET
|
Sana Biotechnology, Inc
SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will...
Sana Biotechnology to Present at September 2024 Investor Conferences
29. August 2024 16:05 ET
|
Sana Biotechnology, Inc
SEATTLE, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will...
Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer
26. August 2024 16:05 ET
|
Sana Biotechnology, Inc
SEATTLE, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the appointment...
Sana Biotechnology Reports Second Quarter 2024 Financial Results and Business Updates
08. August 2024 16:05 ET
|
Sana Biotechnology, Inc
Continue to advance hypoimmune technology in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Enrolling patients in the GLEAM trial for...
Sana Biotechnology Highlights Publication in Nature Biotechnology of Novel In Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as a Treatment for Huntington’s Disease and Other Glial-based Neurodegenerative Conditions
21. Mai 2024 09:00 ET
|
Sana Biotechnology, Inc
Healthy transplanted human glial cells replaced diseased glial cells in the brains of human glial chimeric Huntingtin mice Additional proof-of-concept for the advancement of SC379, Sana’s pluripotent...
Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates
08. Mai 2024 16:05 ET
|
Sana Biotechnology, Inc
Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Ongoing ARDENT trial for SC291 continues in B-cell...
Sana Biotechnology to Present at May and June 2024 Investor Conferences
06. Mai 2024 16:05 ET
|
Sana Biotechnology, Inc
SEATTLE, May 06, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will...
Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
29. Februar 2024 16:05 ET
|
Sana Biotechnology, Inc
Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Early SC291 data from ongoing ARDENT trial in...